Gelonghui, May 8, 丨 Chengda Pharmaceutical (301201.SZ) said on the investor interactive platform that some of the company's products use synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs. The company will then actively promote the application of enzyme catalysis technology and the upgrading of traditional catalytic technology to drive product process upgrading and quality improvement with new technology, providing more possibilities for future drug development. At the same time, the company invested in the establishment of Shanghai Chengjiutai Biomedical Co., Ltd. at the end of 2023, which will help the company lay out the biomedical sector, expand R&D, production and treatment business in the biological cell industry, achieve collaborative development of the company's multiple business lines, and further enhance the company's core competitiveness.
诚达药业(301201.SZ)：部分产品有使用到酶催化等合成生物技术，提升相关产品质量并降低生产成本
Chengda Pharmaceutical (301201.SZ): Some products use synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.